Applied Genetic Technologies Corp. (NASDAQ:AGTC)’s share price fell 1.4% on Tuesday . The stock traded as low as $15.05 and last traded at $15.23, with a volume of 60,294 shares trading hands. The stock had previously closed at $15.44.

Several research firms have weighed in on AGTC. Cantor Fitzgerald restated a “buy” rating and set a $32.00 price target on shares of Applied Genetic Technologies Corp. in a report on Wednesday, June 22nd. Zacks Investment Research cut Applied Genetic Technologies Corp. from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Wells Fargo & Co. restated a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Finally, Roth Capital restated a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Monday, April 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $26.00.

The stock’s 50 day moving average is $15.14 and its 200-day moving average is $15.06. The company’s market capitalization is $273.74 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.06. During the same quarter in the previous year, the business posted ($0.38) EPS. The company earned $12 million during the quarter, compared to analyst estimates of $12.98 million. The company’s revenue was up 4125.4% compared to the same quarter last year. On average, equities research analysts predict that Applied Genetic Technologies Corp. will post ($0.16) earnings per share for the current fiscal year.

A number of large investors recently bought and sold shares of the stock. Russell Frank Co bought a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at $1,541,000. Globeflex Capital L P bought a new stake in Applied Genetic Technologies Corp. during the fourth quarter valued at $1,189,000. Finally, Jennison Associates LLC boosted its stake in Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock valued at $13,823,000 after buying an additional 3,248 shares during the last quarter.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.